FY2025 Earnings Forecast for CYCN Issued By Zacks Research

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) – Stock analysts at Zacks Research issued their FY2025 EPS estimates for Cyclerion Therapeutics in a note issued to investors on Monday, February 2nd. Zacks Research analyst D. Bautz forecasts that the company will earn ($1.34) per share for the year. Zacks Research also issued estimates for Cyclerion Therapeutics’ Q4 2025 earnings at ($0.38) EPS, FY2026 earnings at ($1.20) EPS and FY2027 earnings at ($0.99) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Cyclerion Therapeutics Trading Up 1.9%

Shares of NASDAQ:CYCN opened at $1.10 on Thursday. The stock has a fifty day simple moving average of $1.47 and a two-hundred day simple moving average of $1.99. Cyclerion Therapeutics has a 12-month low of $1.06 and a 12-month high of $4.80. The stock has a market capitalization of $4.32 million, a price-to-earnings ratio of -1.47 and a beta of 0.98.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its quarterly earnings results on Thursday, October 30th. The company reported ($0.30) EPS for the quarter. Cyclerion Therapeutics had a negative return on equity of 24.61% and a negative net margin of 77.02%.The company had revenue of $0.88 million during the quarter.

Institutional Trading of Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 75.62% of the company’s stock.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.